Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01824511 · ClinicalTrials.gov registry record · NA
Effects of Quitting Study A Test of Pre-clinical Findings
A NA study, sponsored by University of Vermont.
- Completed
- Registry status
- NA
- Development phase
- 287
- Enrollment target
NCT01824511: Completed NA study, sponsored by University of Vermont.
NCT01824511 is a NA study that has completed, run by University of Vermont. The registered enrollment target is 287 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01824511, a NA study, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- NA
- Development phase
- 287 participants
- Enrollment target
Study Summary
The most widely-accepted animal model of nicotine withdrawal states stopping nicotine makes rewarding events become less rewarding. The current study will test if this is true in humans. If we find tobacco abstinence does make rewards less rewarding, this would suggest new symptoms to add to official descriptions of nicotine withdrawal. It would also suggest we need to develop new behavioral and pharmacological interventions to correct this problem. If stopping smoking does not make rewards less rewarding, this would suggest this animal model does not apply to the human condition and we need to continue to search for an animal model of tobacco withdrawal that is relevant to smokers stopping smoking.
Primary Outcome
The primary outcome will be the percent choosing the hard task and the amount of responding for a monetary reward on the EEfRT task.
Interventions
- BEHAVIORAL Smokers cease smoking
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-09 |
| Phase | NA |
What the finished NCT01824511 record still lists
NCT01824511 is an interventional study that assigns participants to a tested intervention. The registered 287 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which Smokers cease smoking is the first listed.
NCT01824511 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01824511 about?
NCT01824511 is a clinical study titled "Effects of Quitting Study A Test of Pre-clinical Findings". The most widely-accepted animal model of nicotine withdrawal states stopping nicotine makes rewarding events become less rewarding. The current study will test if this is true in humans. If we find tobacco abstinence does make rewards less rewarding, this would suggest new symptoms to add to officia...
What is the current status of trial NCT01824511?
This trial is currently completed. It is a NA study. The enrollment target is 287 participants. The study started on 2013-04. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01824511?
The interventions under investigation include: Smokers cease smoking (BEHAVIORAL).
Who is sponsoring clinical trial NCT01824511?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01824511's enrollment target sits among peer trials
287 377th of 2000 higher than 1,624 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03094429 · 287 participants · Phase 2
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
- NCT06385080 · 287 participants · Phase 1
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- NCT06919224 · 287 participants · NA
Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia